Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F23%3A10462294" target="_blank" >RIV/00669806:_____/23:10462294 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/23:00131019 RIV/61988987:17110/23:A2402NKW RIV/00216208:11110/23:10462294 RIV/00216208:11140/23:10462294 and 3 more
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=yzElN.jZsy" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=yzElN.jZsy</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ygyno.2023.01.014" target="_blank" >10.1016/j.ygyno.2023.01.014</a>
Alternative languages
Result language
angličtina
Original language name
Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study
Original language description
Objective. The "intermediate-risk" (IR) group of early-stage cervical cancer patients is characterized by nega-tive pelvic lymph nodes and a combination of tumor-related prognostic risk factors such as tumor size >= 2 cm, lymphovascular space invasion (LVSI), and deep stromal invasion. However, the role of adjuvant treatment in these patients remains controversial. We investigated whether adjuvant (chemo)radiation is associated with a survival benefit after radical surgery in patients with IR cervical cancer. Methods. We analyzed data from patients with IR cervical cancer (tumor size 2-4 cm plus LVSI OR tumor size >4 cm; N0; no parametrial invasion; clear surgical margins) who underwent primary curative-intent surgery between 2007 and 2016 and were retrospectively registered in the international multicenter Surveillance in Cervical CANcer (SCCAN) study. Results. Of 692 analyzed patients, 274 (39.6%) received no adjuvant treatment (AT-) and 418 (60.4%) re-ceived radiotherapy or chemoradiotherapy (AT+). The 5-year disease-free survival (83.2% and 80.3%; PDFS = 0.365) and overall survival (88.7% and 89.0%; POS = 0.281) were not significantly different between the AT- and AT+ groups, respectively. Adjuvant (chemo)radiotherapy was not associated with a survival benefit after adjusting for confounding factors by case-control propensity score matching or in subgroup analyses of patients with tumor size >= 4 cm and <4 cm. In univariable analysis, adjuvant (chemo)radiotherapy was not identified as a prognostic factor in any of the subgroups (full cohort: PDFS = 0.365; POS = 0.282). Conclusion. Among patients with IR early-stage cervical cancer, radical surgery alone achieved equal disease -free and overall survival rates to those achieved by combining radical surgery with adjuvant (chemo)radiotherapy.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30214 - Obstetrics and gynaecology
Result continuities
Project
<a href="/en/project/NV19-03-00023" target="_blank" >NV19-03-00023: A prospective observational trial on sentinel lymph node biopsy in patients with early stage cervical cancer – Part 2</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Gynecologic Oncology
ISSN
0090-8258
e-ISSN
1095-6859
Volume of the periodical
170
Issue of the periodical within the volume
March
Country of publishing house
US - UNITED STATES
Number of pages
8
Pages from-to
195-202
UT code for WoS article
000940806800001
EID of the result in the Scopus database
2-s2.0-85147455294